Life Biosciences has initiated human clinical trials for its innovative drug ER-100, which aims to restore vision in individuals suffering from glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). This groundbreaking therapy, which has shown promise in restoring vision in monkeys, is now being tested for safety and side effects in a study involving around 18 adults over the next year. ER-100 is notable for being the first cellular rejuvenation therapy to gain FDA approval for human trials, representing a potential breakthrough in longevity science. According to David Sinclair, co-founder of Life Biosciences and a professor of Genetics at Harvard Medical School, the study will explore whether restoring epigenetic information can improve human health by rejuvenating damaged cells in the optic nerve. This research is pivotal as it delves into the biology of aging and its effects on cellular function. Life Biosciences, based in Boston, is also exploring the application of its technology to combat other age-related diseases, indicating a broader ambition to address the challenges posed by aging across various organ systems.